Erin Bastick
Erin Bastick is a PharmD Candidate 2016, Ohio Northern University, Ada, Ohio, and an inpatient intern at University Hospitals, Cleveland.
New dose of Viibryd approved to treat major depressive disorder in adults
FDA has approved a new dose of vilazodone (Viibryd, Actavis) for the treatment of Major Depressive Disorder (MDD) in adults.
First atypical antipsychotic approved for pediatric patients with bipolar I disorder in 5 years
FDA has approved asenapine (Saphris, Actavis) for treatment of manic or mixed episodes of bipolar I disorder in pediatric patients, ages 10 to 17 years old.
FDA clears closure system to permanently treat varicose veins
The VenaSeal system is newly approved to permanently treat varicose veins by sealing the affected veins using an adhesive agent, known as n-butyl-2-cyanoacrylate, which polymerizes into solid material after being injected into the vein.
FDA expands approval of Revlimid to include newly diagnosed multiple myeloma
FDA expanded approval of lenalidomide (Revlimid, Celgene) for the treatment of multiple myeloma. Revlimid acts as an immunomodulating agent and inhibits the growth of myeloma cells by inducing cell cycle arrest and cell death.
FDA approves Banzel to treat seizures associated with LGS in pediatric patients
FDA has approved rufinamide (Banzel, Eisai) for the treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients.
FDA approves Lenvima for a type of thyroid cancer
FDA has approved lenvatinib (Lenvima, Eisai) for the treatment of progressive, differentiated thyroid cancer.
E-Rx tool for controlled substances launches, integrates with EHRs
Imprivata Confirm ID is the first comprehensive product that simplifies the adoption of DEA requirements for the electronic prescribing of controlled substances.
Humira biosimilar demonstrates positive results for rheumatoid arthritis
Amgen has announced positive results from a clinical study evaluating the safety and efficacy of biosimilar candidate, ABP 501, compared with Humira (adalimumab) in patients with moderate-to-severe rheumatoid arthritis.
FDA approves Lucentis for treatment of diabetic retinopathy in people with DME
FDA has expanded the approved use of ranibizumab (Lucentis, Genentech) to treat diabetic retinopathy in patients with diabetic macular edema (DME).
FDA approves Ibrance to treat metastatic breast cancer
Ibrance is a potent and selective inhibitor of cyclin-dependent kinases (CDKs) 4 and 6, which complex with a regulatory protein, called cyclin, to control cancer cell cycling. The FDA has approved it for use in the treatment of metastatic breast cancer.